ACI-19764 / AC Immune - LARVOL DELTA

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update (GlobeNewswire) - "ACI-19764 small molecule NLRP3 inhibitor is undergoing in vivo proof of concept with results expected in 2025 anticipated to enable investigational new drug (IND) application. Our Morphomer Tau and Morphomer a-syn small molecule aggregation inhibitors have made steady progress with selection of lead candidates expected in 2025."

Pipeline update • Preclinical • CNS Disorders